Program
cliramitug
Also written as “ALXN2220” and “NI006”.
Its studies are mostly in Amyloidosis, led by 2 companies.
Drug pageCliramitug: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 33 open or running | phase 3since Nov 15, 2023 | Nov 15, 2023 | Dec 6, 2027phase 3 · NCT06183931 |
| Neurimmune | 21 open or running | phase 2since Sep 15, 2025 | Mar 11, 2020 | none ahead |
- Named in AstraZeneca’s own pipeline as
cliramitug
, phase 3, as of Oct 30, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseAlexion (AstraZeneca) licensed it from Neurimmune, for worldwide rights.Completed Mar 1, 2022 · Source: AstraZeneca, Mar 1, 2022
History and studies of Neurimmune only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Mar 11, 2020First study: phase 1 study in AmyloidosisFirst studyNCT04360434 · 46 enrolled · France, Germany, Netherlands and more
- Mar 1, 2022Alexion (AstraZeneca) licensed it from NeurimmuneLicenseWorldwide rights · completed · AstraZeneca
- Feb 13, 2025Named cliramitugINNProposed as its International Nonproprietary Name in WHO's List 132 · before, ALXN2220, NI006
- Sep 15, 2025Phase 2 study in AmyloidosisNCT07213583 · 35 enrolled · France, Germany, Netherlands and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Neurimmune leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07213583Amyloidosis · France, Germany, Netherlands and more | 2 | Active, not recruiting | Oct 31, 2026 | 35 |
| NCT04360434Amyloidosis · France, Germany, Netherlands and more | 1 | Completed | Jul 26, 2023 | 46 |
How it is read
Names in the registry
- “ALXN2220”, 4 entries
- “NI006”, 1 entry
Conditions, from the studies’ own filings
- Amyloidosis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.